China Tracker - Details for BioPharm Asia (BFAR)

 BioPharm Asia
Shares Outstanding (MRQ): 50.00 mill 
New Shares / Dilution (TTM): 0.00 mill0.00%
Cash (MRQ): 15.41 mill0.00%
Account Receivables (MRQ): 31.54 mill0.00%
Account Receivables (Q/Q): + 14.77 mill  
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): 77.72% 
Revenue Growth (Y/Y): 68.17%
Net Income Growth (Q/Q): 51.93% 
Net Income Growth (Y/Y): 36.51%
EPS Growth (Y/Y): 36.51%
Net Margin (Q/Q): 14.6% (17.1%)-2.50% 
Net Margin (Y/Y): 14.6% (18.0%)-3.40% 
EPS | P/E (2 MRQ Projection): $0.430.00 
CFPS | P/CF (2 MRQ Projection): -$0.140.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: ACSB & Co.
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.400.00 
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2009-05-07 

 Business Outlook

COVERAGE TERMINATED (Going Dark)
Recent Chain of Events:
2011-06-24 -- Last SEC Filing
2011-02-16 -- CEO Appointment
2011-02-15 -- CEO Resignation
2011-02-14 -- Auditor Engagement
2011-01-30 -- CFO Appointment
2011-01-27 -- CFO Resignation
2011-01-20 -- Auditor Terminated
2010-11-22 -- Last Quarterly/Annual Report: Q3/FY2010 ended September 30, 2010

(Source: Trading China, 2012-09-30)

BioPharm Asia announced today that it is negotiating to acquire a controlling interest in Hubei Holley Zhengyuan Pharmaceutical Company Limited (HBHLZY). HBHLZY, founded in November, 2004, is a wholesale distributor of pharmaceutical products, located at the CBD of Wuhan city, Hubei province. HBHLZY's facilities consist of packaging equipment and a logistical management system. HBHLZY sells 4580 types of products, from 652 suppliers in China and in particular, Hubei province. HBHLZY also acts as a sales agent for over 2000 types of products, including products from Shenzhen SanJiu Pharmaceutical Co., Ltd. and Shenzhen Zhijun Pharmaceutical Co., Ltd.

(Source: Business Wire, 2011-03-28)

On March 25, 2011, China Northern Pharmacy Holding Group Limited, a wholly-owned subsidiary of BioPharm Asia, entered into an agreement to transfer all of the outstanding shares of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (PHARMACY), and its subsidiary Yunnan Silin Pharmaceutical Company Limited (Silin) to City Well International Limited for RMB 200 million, or approximately $30.5 million, based upon prevailing exchange rates.

PHARMACY is an operating company engaged in drug logistics and distribution in the People's Republic of China which as of December 31, 2010 owned and operated 360 retail drug stores. In addition, PHARMACY owns 100% of Silin, a PRC company which is engaged in the sale of medicine products to hospitals and pharmacy shops. Management of PHARMACY and Silin had expressed displeasure at being a public company and the Company determined that it was in the interests of the Company's shareholders to consummate the sale as described herein rather than continue the dispute with the disgruntled management and, potentially, lose the entire value of the operations of PHARMACY and Silin without receiving any compensation. It is anticipated that the closing of the transfer will occur on or before April 1, 2011.

Management of the Company will seek to apply the net proceeds of the transaction to the acquisition of one or more new businesses.

(Source: 8-K Filing, 2011-03-28)

    see all Business Outlook notes

 Investor Presentations
2009-10-23 (HTML)   VIEW
BFAR
Healthcare & Drugs
SCORE
4
UNDER REVIEW
READ: Score Cards Explained
SAFETY/RISK SCORE
EXTREME RISK
DETAILS: Safety/Risk Model for BFAR
Current Price:  n/a
F10k Day (2009-05-05): -100.00%$2.00
2009 Close: -100.00%$2.00
2010 Close: -100.00%$2.88
2011 Close: -100.00%$0.05
High (2012-04-03): -100.00%$0.12
Low (2012-10-05): -100.00%$0.02
Exchange:
Market Capitalization: n/a
Total Shares: 50.00 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2010-09-30
Revenue (MRQ): 44.70 mill
Net Income (MRQ): 6.53 mill
Op. Cash Flow (MRQ): -4.59 mill
all financial data provided without warranty